A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Latest Information Update: 22 Sep 2025
At a glance
- Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
- Indications Multiple organ failure; Sepsis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Enlivex Therapeutics
Most Recent Events
- 19 Aug 2025 Status changed from active, no longer recruiting to completed.
- 11 Apr 2024 According to an Enlivex Therapeutics media release, Company expects to release further details about the study in a forthcoming presentation.
- 11 Apr 2024 Results presented in the Enlivex Therapeutics Media Release